Jiri Beran1. 1. School of Medicine & University Hospital, Department of Infectious Diseases, Hradec Králové, Czech Republic. jiri.beran@vakcinace.cz
Abstract
BACKGROUND: High susceptibility to infections including the hepatitis B virus (HBV) causes increased morbidity and mortality in patients with end stage renal disease. HBV vaccination is recommended for all patients undergoing dialysis; however, antibody response is much lower than in healthy individuals. OBJECTIVE: This review discusses the clinical experience with HBV vaccine with a novel adjuvant system among dialysed patients. METHOD: A new adjuvanted HBV vaccine (Fendrix(), GlaxoSmithKline Biologicals, Rixensart, Belgium) contains as active substance 20 microg recombinant hepatitis B surface antigen produced in Saccharomyces cerevisiae and the novel adjuvant system composed of aluminum salt and 3-O-desacyl-4'-monophosphoryl lipid A (AS04). CONCLUSION: HBV-AS04 vaccine has a good safety profile with clinically acceptable reactions similar to standard HBV vaccines and has elicited earlier antibody response and higher antibody titres in pre and haemodialysis patients as compared with four double doses of standard HBV vaccine.
BACKGROUND: High susceptibility to infections including the hepatitis B virus (HBV) causes increased morbidity and mortality in patients with end stage renal disease. HBV vaccination is recommended for all patients undergoing dialysis; however, antibody response is much lower than in healthy individuals. OBJECTIVE: This review discusses the clinical experience with HBV vaccine with a novel adjuvant system among dialysed patients. METHOD: A new adjuvanted HBV vaccine (Fendrix(), GlaxoSmithKline Biologicals, Rixensart, Belgium) contains as active substance 20 microg recombinant hepatitis B surface antigen produced in Saccharomyces cerevisiae and the novel adjuvant system composed of aluminum salt and 3-O-desacyl-4'-monophosphoryl lipid A (AS04). CONCLUSION:HBV-AS04 vaccine has a good safety profile with clinically acceptable reactions similar to standard HBV vaccines and has elicited earlier antibody response and higher antibody titres in pre and haemodialysis patients as compared with four double doses of standard HBV vaccine.
Authors: Alba Vilajeliu; Víctor-Guillermo Sequera; Alberto L García-Basteiro; Elisa Sicuri; Marta Aldea; César Velasco; José M Bayas Journal: Hum Vaccin Immunother Date: 2016-04-22 Impact factor: 3.452
Authors: Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett Journal: Vaccine Date: 2012-02-22 Impact factor: 3.641